Allspring Global Investments Holdings LLC Has $1.42 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Allspring Global Investments Holdings LLC lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 1,005.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 22,603 shares of the company’s stock after buying an additional 20,558 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Vaxcyte were worth $1,419,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. increased its position in Vaxcyte by 0.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company’s stock worth $3,211,000 after purchasing an additional 296 shares in the last quarter. Arizona State Retirement System grew its stake in shares of Vaxcyte by 4.9% during the fourth quarter. Arizona State Retirement System now owns 20,988 shares of the company’s stock worth $1,318,000 after buying an additional 977 shares during the last quarter. Ellsworth Advisors LLC increased its holdings in shares of Vaxcyte by 2.6% during the fourth quarter. Ellsworth Advisors LLC now owns 8,060 shares of the company’s stock worth $506,000 after buying an additional 207 shares in the last quarter. Legato Capital Management LLC lifted its stake in shares of Vaxcyte by 14.0% in the 4th quarter. Legato Capital Management LLC now owns 12,196 shares of the company’s stock valued at $766,000 after acquiring an additional 1,498 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Vaxcyte by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 8,284,246 shares of the company’s stock valued at $422,331,000 after acquiring an additional 47,872 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Trading Up 1.3 %

Shares of PCVX opened at $61.60 on Tuesday. The company has a market capitalization of $6.70 billion, a PE ratio of -14.92 and a beta of 0.89. The stock’s 50-day moving average price is $69.09 and its two-hundred day moving average price is $61.21. Vaxcyte, Inc. has a 12 month low of $41.57 and a 12 month high of $82.04.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same period in the prior year, the business earned ($0.73) earnings per share. Equities research analysts predict that Vaxcyte, Inc. will post -4.18 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on PCVX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Bank of America upped their price objective on Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research report on Wednesday, April 10th. Four investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $78.50.

Insider Activity

In related news, CEO Grant Pickering sold 30,000 shares of Vaxcyte stock in a transaction on Monday, January 29th. The shares were sold at an average price of $66.03, for a total transaction of $1,980,900.00. Following the completion of the transaction, the chief executive officer now owns 375,814 shares of the company’s stock, valued at $24,814,998.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $61.27, for a total transaction of $490,160.00. Following the transaction, the chief financial officer now directly owns 95,679 shares in the company, valued at approximately $5,862,252.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Grant Pickering sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $66.03, for a total transaction of $1,980,900.00. Following the sale, the chief executive officer now directly owns 375,814 shares of the company’s stock, valued at approximately $24,814,998.42. The disclosure for this sale can be found here. In the last three months, insiders have sold 94,577 shares of company stock valued at $6,471,835. 3.60% of the stock is currently owned by insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.